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Abstract 1 
Background: The optimal anticoagulant following catheter-based therapy of acute 2 
iliofemoral deep vein thrombosis (IFDVT) is unknown.  3 
 4 
Methods: From the Swiss Venous Stent registry, an ongoing prospective cohort study, 5 
we performed a subgroup analysis of patients with acute IFDVT who underwent 6 
catheter-based early thrombus removal followed by nitinol stent placement. Duplex 7 
ultrasound and Villalta scores were used to determine patency rates and incidence of 8 
the post-thrombotic syndrome (PTS) in patients treated with either rivaroxaban (n=73) 9 
or a vitamin K-antagonist (VKA; n=38) for a minimum duration of 3 months.  10 
 11 
Results: Mean follow-up duration was 24±19 months (range 3 to 77 months). 12 
Anticoagulation therapy was time-limited (3 to 12 months) in 56% of patients (47% in 13 
the rivaroxaban group and 58% in the VKA group, p=0.26), with shorter mean duration 14 
of anticoagulation in the rivaroxaban group (180±98 days versus 284±199 days, 15 
p=0.01). Overall, primary and secondary patency rates at 24 months were 82% (95%CI, 16 
71-89%) and 95% (95%CI, 87-98%), respectively, with no difference between the 17 
rivaroxaban (87% [95%CI, 76-94%] and 95% [95%CI, 85-98%]) and the VKA group 18 
(72% [95%CI, 52-86%] and 94% [95%CI, 78-99%]; p>0.10 for both). Overall, 86 (86%) 19 
patients were free from PTS at latest follow-up, with no difference between the 20 
rivaroxaban and the VKA groups (57 [85%] versus 29 [88%]; p=0.76). Two major 21 
bleeding complications (1 in each group) occurred in the peri-interventional period, 22 
without any major bleeding thereafter.  23 
 24 
4  
Conclusions: In patients with acute IFDVT treated with catheter-based early thrombus 1 
removal and venous stent placement, the effectiveness and safety of rivaroxaban and 2 
VKA appear to be similar.   3 
 4 
Clinical Trial Registration: The study is registered on the National Institutes of Health 5 
website (ClinicalTrials.gov; identifier NCT02433054). 6 
 7 
Keywords: Anticoagulation; catheter-directed thrombolysis; deep vein thrombosis; 8 
post-thrombotic syndrome; rivaroxaban 9 
5  
Introduction 1 
Deep vein thrombosis (DVT) is associated with severe morbidity and mortality. It is the 2 
most frequent type of venous thromboembolism (VTE) and responsible for 3 
approximately 800.000 deaths per year in the European Union and the United States 4 
combined.[1, 2] The most important long term complications of DVT are the post-5 
thrombotic syndrome (PTS) and recurrent VTE. Patients with iliofemoral DVT (IFDVT) 6 
are at particularly high risk, with up to 50% of these patients suffering from the PTS,[3-7 
5] most likely due to the strategic anatomic location with low recanalization rates of 8 
these veins.[6] Furthermore, patients with IFDVT have a twofold higher risk for 9 
recurrent VTE under therapeutic anticoagulation therapy than patients with more distal 10 
DVT.[7] 11 
Early endovascular thrombus removal therapy, i.e. catheter-directed thrombolysis 12 
(CDT) or pharmacomechanical thrombectomy (PMT), reduces the risk of moderate or 13 
severe PTS by removing the occluding thrombus and by preventing secondary venous 14 
valve damage.[8-10] Up to 80% of patients with IFDVT have an underlying obstructive 15 
iliac vein lesion,[11, 12] which can be treated by stent placement once the acute 16 
thrombus has been removed.[13] Venous patency rates 6-24 months after catheter-17 
based thrombus removal with or without stent placement in patients with IFDVT ranged 18 
between 72% and 100%.[14-16] Based on the results of small randomized-controlled 19 
trials and prospective cohort studies, clinical practice guidelines suggest the use of 20 
early thrombus removal strategies and adjunctive use of venous stents for residual 21 
obstructive vein lesions as first-line therapy in selected patients with acute IFDVT and 22 
low bleeding risk.[17-20] 23 
Anticoagulation therapy remains the cornerstone for patients with DVT. Recently, 24 
direct oral anticoagulants (DOAC), including rivaroxaban, have replaced vitamin K-25 
6  
antagonists (VKA) as first-line therapy in most DVT patients, due to reduced risk of 1 
major bleeding [21-24] and increased patient comfort. DOACs may become an 2 
alternative to low-molecular-weight heparins (LMWH) in patients with cancer-3 
associated thrombosis and low risk of bleeding.[25, 26] However, the optimal type and 4 
duration of anticoagulant therapy after early thrombus removal for acute IFDVT, 5 
particularly in the presence of venous stents, is still unclear. Several studies have 6 
investigated the efficacy and safety of early thrombus removal and venous stent 7 
placement, but little attention has been paid to exploration and verification of 8 
antithrombotic therapy.[3, 9, 13, 15, 27-32] The majority of available studies reported 9 
time-limited anticoagulation with VKA after catheter-based therapy, but stent 10 
placement rates varied significantly between the studies (7% – 100%). Although there 11 
is a consensus that anticoagulation therapy is preferable to antiplatelet therapy, it 12 
remains unclear whether DOAC are equally effective as VKA in this setting.  13 
Unfortunately, recent large randomized controlled trials comparing the different 14 
DOACs with LMWH/VKA systematically excluded patients undergoing early thrombus 15 
removal or stent placement.[22, 24, 33, 34]. At present, consensus statement 16 
guidelines do not specifically address anticoagulant therapy in patients undergoing 17 
endovascular treatment of DVT.[19, 35]  18 
The aim of our study was to report the effectiveness and safety of rivaroxaban and 19 
VKA in patients with early endovascular thrombus removal and stent placement for 20 
acute IFDVT. 21 
7  
Methods 1 
Study design 2 
We performed a subgroup analysis derived from the Swiss Venous Stent registry, an 3 
ongoing prospective study enrolling consecutive patients who received venous nitinol 4 
stents at the University Clinic of Angiology in Bern since July 2011. We included all 5 
patients with acute IFDVT who underwent endovascular thrombus removal therapy 6 
(CDT and/or PMT) followed by stent placement. All patients had at least one clinical 7 
visit and duplex ultrasound study. Exclusion criteria were the inability to provide 8 
informed consent, age below 18 years, estimated life expectancy <3 months, 9 
endovascular therapy without stent placement, and post-interventional anticoagulation 10 
therapy other than rivaroxaban or VKA.  For the current analysis, 11 patients who 11 
underwent endovascular therapy for IFDVT but received parenteral anticoagulation 12 
therapy only due to cancer associated IFDVT were excluded. During the study period, 13 
the stent placement rate in patients with IFDVT treated with early thrombus removal 14 
was 80%.[13, 16] The registry and participant consent form were approved by the 15 
Swiss Ethics Committee on research involving humans. The study is registered on the 16 
National Institutes of Health website (ClinicalTrials.gov; identifier NCT02433054). All 17 
authors had full access to all the data in the study. 18 
 19 
Data and subgroup definitions 20 
For all enrolled patients, baseline demographic information, disease-specific 21 
information (thrombosis localization, involved venous segments, symptom onset, 22 
recurrence), comorbid conditions, risk factors, and anticoagulation therapy 23 
(anticoagulant type, treatment duration, bleeding complications) were recorded using 24 
8  
a standardized case report form. Procedural data included type of catheter intervention 1 
(CDT/PMT), duration, dose and success of thrombolysis, and type and number of 2 
implanted stents.  3 
For the purpose of the present analysis, we predefined two patient subgroups: 4 
1. Patients treated with rivaroxaban for a minimum of 3 months. 5 
2. Patients treated with VKA (targeting INR of 2.0 – 3.0) for a minimum of 3 months. 6 
 7 
Diagnosis and anticoagulation therapy 8 
IFDVT was objectively confirmed by duplex ultrasound or contrast-enhanced 9 
computed tomography. Acute DVT was defined as symptom duration ≤14 days; 10 
subacute DVT as thrombosis for which symptoms were present for 15 to 28 days. DVT 11 
was defined as provoked in the presence of recent immobilization (bed ridden for >72 12 
h, plaster cast, or long-distance travel of >6 h), postoperative, trauma, hormone 13 
therapy (oral contraceptives, postmenopausal hormonal replacement, tamoxifen use), 14 
active cancer, pregnancy or postpartal period, or after acute medical illness (e.g. 15 
pneumonia, congestive heart failure).[36]  16 
On admission, an intravenous bolus of heparin of 80 units per kg body weight was 17 
administered. If the patient was already on full anticoagulation therapy, the initial bolus 18 
was omitted. In case of CDT, patients were treated with intravenous heparin 19 
administered through the venous access sheath throughout the thrombolysis until time 20 
of second look venography, adjusted to target a factor Xa inhibition activity of 0.3 to 21 
0.7 IU/ml. Within 24 h after full completion of the endovascular therapy, heparin was 22 
converted to either VKA (with overlapping LMWH for at least 5 days) or rivaroxaban. 23 
The choice of anticoagulation therapy was up to the treating vascular specialist, and 24 
there was no predefined algorithm for the allocation of the anticoagulation therapy. 25 
9  
VKA dosage was adapted by the general practitioner and we did not collect data on 1 
the time in the therapeutic range in the VKA group. We did not prescribe antiplatelet 2 
therapy after venous stenting by default, unless otherwise indicated. 3 
 4 
Catheter-based therapy 5 
Details on the CDT and PMT procedures have been published previously.[13, 37] In 6 
patients with thrombus extension into the popliteal veins or into the inferior vena cava, 7 
initial CDT was performed with a standard multi-sidehole catheter (e.g. Craigg-8 
McNamara®, ev3 Endovascular, Plymouth, MN, USA) or an ultrasound-assisted 9 
catheter system (EkoSonic MACH4 Endovascular System®, EKOS Corporation, 10 
Bothell, WA, USA) according a standardized catheter thrombolysis protocol (20 mg 11 
recombinant tissue plasminogen activator [Actilyse; Boehringer Ingelheim, Ingelheim 12 
am Rhein, Germany] over 15 h ).[13, 16] In case of residual thrombi, either prolonged 13 
CDT or additional PMT using an AngioJet device (Boston Scientific, Minneapolis, MN, 14 
USA) was performed. If the thrombus burden was less extensive, single session PMT 15 
with an AngioJet device without prior CDT was an option.[37] Significant residual vein 16 
stenosis (visualized by digital subtraction venography in two orthogonal views, or by 17 
intravascular ultrasound if venography was equivocal), defined as luminal narrowing 18 
>50%, absent antegrade flow, or presence of collateral flow at the site of suspected 19 
stenosis, were treated by balloon angioplasty and stent implantation as previously 20 
described.[37]   21 
 22 
Clinical follow-up 23 
Clinical follow-up visits were routinely performed at our outpatient clinic by vascular 24 
specialists at 3, 6, 12 months, followed by yearly visits. At each visit, symptoms and 25 
10  
clinical signs of PTS were recorded using the Villalta score and revised venous clinical 1 
severity scores (rVCSS).[38, 39] Current anticoagulation therapy and recent VTE 2 
complications were assessed. Patients received a standardized duplex sonography 3 
examination at each follow-up visit, scanning for thrombotic and post-thrombotic 4 
changes of both the treated stent segments and the inflow vessels.  5 
 6 
Definition of outcomes 7 
Technical success was defined as antegrade flow and maximal luminal stenosis of 8 
≤30% at termination of the procedure by venography, and evidence of spontaneous 9 
flow in the treated vein segment by duplex sonography.[13] Primary patency rate was 10 
defined as the percentage of patients with primary treatment success and without the 11 
occurrence of either thrombosis of the treated segment or re-intervention to maintain 12 
patency of the treated segment. Primary assisted patency rate was defined as the 13 
percentage of patients with primary treatment success and without the occurrence of 14 
thrombosis of the treated segment, irrespectively of any interval therapy. Secondary 15 
patency rate was defined as the percentage of patients with primary treatment success 16 
and without the occurrence of permanent loss of flow in the treated segment, 17 
irrespective of any interval therapy.[40]  18 
In order to distinguish between the bleeding complications due to the endovascular 19 
intervention and those due to the anticoagulation therapy thereafter, we defined peri-20 
interventional bleeding complications as bleeding complications within the first 72 h 21 
and post-interventional bleeding complications as bleeding complications ≥72 h after 22 
the end of the catheter-based treatment. Bleeding complications were classified 23 
according to the International Society on Thrombosis and Haemostasis, where major 24 
bleedings are either 1) fatal bleeding, 2) symptomatic bleeding in a critical area or 25 
11  
organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or 1 
pericardial, or intramuscular with compartment syndrome, and/or 3) bleeding causing 2 
a drop in hemoglobin level of 20g/L, or leading to transfusion of ≥2 units of packed red 3 
blood cells. Minor bleedings are less severe bleedings not included in the definition of 4 
major bleedings.[41] 5 
Presence of PTS was defined as a total Villalta score of ≥5 points, or the presence of 6 
a venous ulcer. PTS was classified as mild (Villalta score of 5 to 9 points), moderate 7 
(10 to 14 points), or severe (≥15 points, or presence of venous ulcers).  8 
 9 
Statistical analysis 10 
Data are presented as means ± standard deviations or absolute numbers and 11 
percentages for continuous and categorical variables, respectively. Categorical 12 
outcomes are presented as percentage with 95% confidence intervals (95%CI).  13 
P-values for differences between the groups were calculated from unpaired t-tests or 14 
Wilcoxon rank test where appropriate for continuous variables, and chi-square test for 15 
categorical variables. The cumulative risks of patency rates were estimated with the 16 
Kaplan–Meier method, and compared by use of a univariate Cox-regression analysis. 17 
In addition, we compared time to events for primary and secondary patency rates 18 
between the groups using the log-rank test. A p-value <0.05 was considered 19 
statistically significant. Data were analyzed using STATA 14.1 software (STATACorp 20 
LP, College Station, TX, USA). 21 
12  
Results 1 
Baseline characteristics and thrombosis extension 2 
A total of 111 patients with a mean age of 46 ± 20 years were included.  Baseline 3 
characteristics were similar in both groups except for age, immobilization, hormone 4 
therapy and duration of symptoms (Table 1). All patients had thrombotic occlusion of 5 
the common or the external iliac veins, with thrombus extension to the common femoral, 6 
femoral, popliteal veins or the inferior vena cava in 79 (71%), 51 (46%), 38 (34%) and 7 
22 (20%) patients, respectively, without difference between both study groups (Table 8 
1).  9 
 10 
Procedural data 11 
Primary treatment success was achieved in all patients. CDT alone or in combination 12 
with PMT was performed in 102 (92%) patients, with no difference between the two 13 
study groups (Table 2). Procedural details including treatment duration, dose, 14 
thrombolysis success and number of stents were similar in both groups (Table 2).  15 
 16 
Anticoagulation therapy 17 
All patients received anticoagulation therapy for a minimum duration of three months, 18 
with 73 (66%) patients being treated with rivaroxaban and 38 (34%) patients with VKA 19 
(Table 2). Anticoagulation was prescribed for a limited duration in 56 (50%) of patients, 20 
and for extended duration in 44 (40%) of patients. In 11 (10%) patients, the duration 21 
(limited or extended) of anticoagulation therapy was not yet determined at the last 22 
follow-up visit. In patients with anticoagulation of limited duration, mean duration of 23 
anticoagulation therapy was shorter in the rivaroxaban group than in the VKA group 24 
13  
(180±98 days versus 284±199 days, p=0.01). At baseline, a total of 11 (10%) patients 1 
were on antiplatelet therapy, 7 (9.7%) in the rivaroxaban group and 4 (10.5%) in the 2 
VKA group (p=0.89). In the post-interventional period, 17 (15.5%) patients were treated 3 
with antiplatelet therapy in addition to anticoagulation, with more patients treated in the 4 
VKA group than in the rivaroxaban group (11 [28.9%] versus 6 [8.3%]; p=0.004), for a 5 
median duration of 152 days (range 87 to 1123 days).  A total of 5 (4.5%) patients 6 
received antiplatelet therapy during follow-up (3 [4.2%] in the rivaroxaban group versus 7 
2 [5.3%] in the VKA group; p=0.79). 8 
 9 
Patency rates 10 
The mean follow-up duration was 24±19 months (range 3 to 77 months), with a shorter 11 
follow-up duration in the rivaroxaban group (22±16 months) than in the VKA group 12 
(31±23 months, p=0.02). Overall, primary patency rates at 12 and 24 months were 13 
88% (95%CI, 80-93%) and 82% (95%CI, 71-89%), respectively, with no difference 14 
between the rivaroxaban group (90% [95%CI, 80-95%] and 87% [95%CI, 76-94%]) 15 
and the VKA group (85% [95%CI, 68-94%] and 72% [95%CI, 52-86%], p=0.12, Figure 16 
1), with a non-significant hazard ratio of 0.49 (95%CI; 0.20-1.20) in favour of 17 
rivaroxaban in univariate Cox regression analysis. Among the baseline characteristics 18 
from Table 1, only active malignancy (hazard ratio of 10.2; 95%CI 2.9-36.4) was 19 
significantly associated with reduced primary patency. 20 
Overall, primary assisted patency rates at 12 and 24 months group were 90% (95%CI, 21 
82-95%) and 88% (95%CI, 80-94%), respectively, with no difference between the 22 
rivaroxaban group (91% [95%CI, 82-96%] and 89% [95%CI, 79-95%]) and the VKA 23 
group (88% [95%CI, 71-95%] and 88% [95%CI, 71-95%], p=0.34). Overall, secondary 24 
patency rates at 12 and 24 months were 96% (95%CI, 89-98%) and 95% (95%CI, 87-25 
14  
98%), respectively, with no difference between the rivaroxaban group (97% [95%CI, 1 
89-99%] and 95% [95%CI, 85-98%]) and the VKA group (94% [95%CI, 78-98%] and 2 
94% [95%CI, 78-99%], p=0.83, Figure 2). 3 
 4 
Clinical outcomes and complications during follow-up  5 
Clinical follow-up data were available for 100 (90%) patients. In 11 (10%) patients with 6 
available duplex ultrasound examinations, the Villalta score could not be calculated 7 
because of missing data for individual score items. Overall, 86 (86%) patients were 8 
free from PTS at latest follow-up, with no difference between the rivaroxaban and the 9 
VKA groups (57 [85%] versus 29 [88%]; p=0.76; Table 3): 13 (13%) patients (9 [13%] 10 
in the rivaroxaban versus 4 [12%] in the VKA group; p=0.85) developed a mild PTS, 11 
and 1 (1%) patient in the rivaroxaban group developed a moderate PTS. None 12 
developed severe PTS or leg ulcers. Overall, the final mean Villalta score was 1.6 ± 13 
2.1 (1.8 ± 2.3 in the rivaroxaban versus 1.5 ± 2.0 in the VKA group;  p=0.55) and the 14 
mean rVCSS was 2.4 ± 2.4 (2.6 ± 2.6 in the rivaroxaban versus 2.0 ± 2.1 in the VKA 15 
group;  p=0.30) at latest follow-up (Table 3).  16 
 17 
Overall, 15 (14%) patients developed a recurrent VTE during follow-up: 13 (12%) had 18 
thrombotic stent reocclusion, with 5 (5%; 3 [4%] in the rivaroxaban and 2 [5%] in the 19 
VKA group;  p=0.78) patients having an early stent thrombosis (within 30 days), and 8 20 
(4 [5%] in the rivaroxaban and 4 [11%] in the VKA group;  p=0.33) patients had late 21 
stent thrombosis (after 30 days). One (1%) patient in the rivaroxaban group had a 22 
symptomatic non-fatal pulmonary embolism, and 1 (1%) patient in the VKA group had 23 
a contralateral DVT. 24 
 25 
15  
Bleeding complications occurred in 11 (10%) patients, with 6 (8%) in the rivaroxaban 1 
and 5 (13%) in the VKA group (p=0.41). Major bleeding complications occurred in 2 2 
(2%) patients, both in the peri-interventional period, with 1 (1%; retroperitoneal 3 
hemorrhage requiring 4 U of packed blood cells) in the rivaroxaban and 1 (3%, 4 
bleeding complication at the inguinal puncture site requiring re-intervention with 5 
delayed wound healing) in the VKA group (p=0.64).  Minor bleeding complications 6 
occurred in 9 (8%) patients, with 5 (7%) in the rivaroxaban and 4 (11%) in the VKA 7 
group (p=0.50). Four (44%) of them occurred in the peri-interventional period (all minor 8 
bleeding complications at the venous puncture site), and 5 (56%) in the post-9 
interventional period (increased menstrual bleedings, epistaxis, bleeding after venous 10 
blood sampling). 11 
16  
Discussion 1 
We report the first larger, prospective cohort study on post-intervention anticoagulation 2 
therapy following catheter-based early thrombus removal and stent placement in 3 
patients with acute IFDVT. We found that the effectiveness and safety of rivaroxaban 4 
appeared to be at least as good as VKA to preserve stent patency without an increased 5 
risk for bleeding complications or VTE recurrence. 6 
Currently, anticoagulation therapy remains standard of care for the treatment of DVT, 7 
and there is an ongoing debate whether an additional early thrombus removal strategy 8 
is superior to conservative therapy, at least in selected patients at high risk of PTS. 9 
Several studies have linked early thrombus removal therapy to decreased occurrence 10 
of PTS.[3, 13, 15, 27-29] The randomized controlled TORPEDO (Thrombus 11 
Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous 12 
Occlusion) and CaVenT (Catheter-directed Venous Thrombolysis) trials showed a 13 
23% and 28% absolute risk reduction in PTS occurrence after 30 and 60 months, 14 
respectively.[15, 27] In contrast, the largest, most recent ATTRACT (Thrombus 15 
Removal with Adjunctive Catheter-Directed Thrombolysis Randomized Trial) study 16 
failed to confirm these findings, as catheter-based therapy only prevented moderate-17 
to-severe PTS.[10]  None of these trials specifically reported on patency or clinical 18 
outcomes according to different anticoagulation treatment regimens. To our knowledge, 19 
there are no other studies available comparing the efficacy and safety of various 20 
anticoagulation therapy regimens in the setting of early thrombus removal for acute 21 
IFDVT.  22 
The average age in our study population (46 years) was somewhat lower than in the 23 
three previous trials (53-61 years).[10, 15, 28] In the CaVenT, TORPEDO, and 24 
ATTRACT trials, VKA were the most frequently prescribed anticoagulants. The mean 25 
duration of anticoagulation therapy in patients with limited duration anticoagulation in 26 
17  
the ATTRACT trial (211 days) was similar compared to our study (219 days), the two 1 
other trials did not report on the duration of anticoagulation therapy. In contrast to our 2 
cohort of IFDVT patients, of whom all received a venous stent, only 17%, 30%, and 3 
24% of patients included in the aforementioned trials received venous stents, 4 
respectively. Unfortunately, the ATTRACT trial did not investigate venous patency. 5 
While the presence of a stent as foreign body in the venous system might be 6 
considered a risk factor for early re-thrombosis on one hand, the elimination of the 7 
obstructing vein lesion is likely to reduce the long-term risk of ipsilateral recurrent DVT 8 
on the other. It remains unknown if venous stent placement in this setting has an effect 9 
on VTE recurrence and as a consequence on the required duration of anticoagulation 10 
therapy.  11 
Currently, there is a great inconsistency in the use of antithrombotic agents after 12 
endovascular therapy of IFDVT. According to a recent international survey completed 13 
by 106 experts, half of them reported to use LMWH then VKA for 6 to 12 months for a 14 
presented case scenario of an acute IFDVT treated with CDT and venous stent 15 
placement, and one third of the experts reported the use of DOACs. Antiplatelet agents 16 
were used in combination with either DOACs or VKA by 27% and long-term 17 
anticoagulation with either DOACs or VKA was used by 12% of the experts.[42] 18 
The standard of care for decades with VKA (with concomitant LMWH for the first few 19 
days) for the management of acute DVT has recently been replaced by DOACs, either 20 
directly after the diagnosis (e.g. rivaroxaban and apixaban) or preceded by LMWH for 21 
5-10 days (e.g. dabigatran and edoxaban).[35] However, none of the DOACs has been 22 
tested in patients treated with early thrombus removal or venous stenting.[22, 24, 33, 23 
34] Our study results add to the current knowledge that rivaroxaban, started within 24 24 
hours after the end of the endovascular procedure, appears to be at least as effective 25 
and safe as the combination LMWH/VKA without an increase in bleeding complications. 26 
18  
Most bleeding complications occurred in the peri-procedural period and are certainly 1 
due to the endovascular intervention itself, while in the post-interventional period only 2 
few minor bleedings occurred in both study groups.  3 
The clinical outcomes were favourable in both study groups, with only 14% of patients 4 
having a PTS after a mean follow-up of 24 months. Our results confirm the previous 5 
report from the pooled data of the randomized controlled BERNUTIFUL (BERN 6 
Ultrasound-assisted Thrombolysis for Ilio-Femoral deep vein thrombosis versUs 7 
standard catheter directed thromboLysis) trial, which reported an overall incidence of 8 
PTS at 12 months follow-up of 11%.[16] These results are in contrast with the relatively 9 
high incidence of PTS at 24 months in the interventional study arms of the CaVenT 10 
(41%) and ATTRACT (31%) trials, [3, 10] which might be due to the much higher stent 11 
placement rate in the BERNUTIFUL trial (80%) and the present study.[16]  12 
Our study has several limitations. First, it was not randomized, and selection bias may 13 
have been present since anticoagulation choice was left to the treating physician. 14 
Second, patients in the VKA group had longer symptom duration, and INR levels and 15 
time in therapeutic range were not assessed. This may have influenced patency rates 16 
and the incidence of the PTS. Third, sample size was moderate, and group sizes were 17 
unequal. In a post-hoc analysis, the power to detect meaningful differences between 18 
the study groups based on our sample size and the observed primary patency rates 19 
was only 50%. Therefore, our results are hypothesize generating only and do not allow 20 
statements regarding the superiority of the various treatments. Fourth, patients with 21 
early thrombus removal without venous stent placement were not included in the Swiss 22 
Venous Stent registry. Last, the study was conducted in a single Swiss tertiary hospital, 23 
therefore limiting the generalizability of our findings.  24 
19  
In conclusion, rivaroxaban initiated after early thrombus removal and venous stent 1 
placement for acute IFDVT appeared to have similar effectiveness and rates of 2 
bleeding compared to standard therapy with LMWH as a bridge to VKA.  3 
20  
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Figures 
Figure 1: Primary patency in the VKA and DOAC group  
 
Kaplan-Meier curves with primary patency rates for the VKA and rivaroxaban groups 
[log-rank, p=0.11]. The reported standard error was 8.6% for the VKA group and 4.3% 
for the rivaroxaban group at 2 years follow up.  Standard error for VKA group exceeds 
10% at 3 years follow up (10.1%).  
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Figure 2: Secondary patency in the VKA and DOAC group  
 
Kaplan-Meier curves with secondary patency rates for the VKA and the rivaroxaban 
groups [log-rank, p=0.83]. The reported standard error was 4.2% for VKA group and 
3.0% for the rivaroxaban group at 3 years follow up. 
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Table 1. Baseline characteristics  
  
Total                       
(n = 111) 
Rivaroxaban   
(n = 73) 
VKA  
(n = 38) 
P 
Value 
Demographics 
          
 
Age (years) 46 ± 20 49 ± 21 40 ± 18 0.02 
 
Women 70 
 
(63) 42 
 
(58) 28 
 
(74) 0.09 
 
Body mass index (kg/m2) 26.3 ± 5.6 26.6 ± 5.9 25.0 ± 3.9 0.26 
            
Risk factors and comorbidities 
          
 
Immobilization* (< 3 months) 42 
 
(38) 33 
 
(45) 9 
 
(24) 0.02 
 
Current smoking 12 
 
(11) 8 
 
(11) 4 
 
(11) 0.86 
 
Hormone therapy † 35 
 
(32) 19 
 
(26) 16 
 
(42) 0.07 
 
Obesity 23 
 
(21) 16 
 
(22) 7 
 
(18) 0.69 
 
Arterial hypertension 24 
 
(22) 19 
 
(26) 5 
 
(13) 0.15 
 
Recent hospitalization (< 3 months) 22 
 
(20) 17 
 
(23) 5 
 
(13) 0.21 
 
Varicose veins or previous surgery 
for varicose veins 17 
 
(15) 13 
 
(18) 4 
 
(11) 0.31 
 
Known previous VTE 26 
 
(23) 19 
 
(26) 7 
 
(18) 0.41 
 
Known thrombophilia 17 
 
(15) 9 
 
(12) 8 
 
(21) 0.24 
 
Dyslipidemia 8 
 
(7) 6 
 
(8) 2 
 
(5) 0.33 
 
Chronic pulmonary disease 7 
 
(6) 4 
 
(5) 3 
 
(8) 0.62 
 
Severe infection or sepsis (< 3 
months) 9 
 
(8) 4 
 
(5) 5 
 
(13) 0.16 
 
Peripheral artery disease 5 
 
(5) 3 
 
(4) 2 
 
(5) 0.78 
30  
 
Active cancer or treatment (< 6 
months) 4 
 
(4) 3 
 
(4) 1 
 
(3) 0.69 
 
Recent trauma (< 4 weeks) 7 
 
(6) 6 
 
(8) 1 
 
(3) 0.26 
 
Coronary artery disease 3 
 
(3) 3 
 
(4) 0 
 
(0) 0.20 
 
Diabetes 9 
 
(8) 7 
 
(10) 2 
 
(5) 0.45 
 
Acute rheumatic disease (< 3 
months) 3 
 
(3) 3 
 
(4) 0 
 
(0) 0.21 
 
Recent surgery (< 4 weeks) 10 
 
(9) 9 
 
(12) 1 
 
(3) 0.10 
 
Provoked DVT 78 
 
(70) 50 
 
(68) 28 
 
(74) 0.57 
  
 
         
Affected leg 
          
 
Left leg DVT 79  (71) 51 
 
(70) 28 
 
(74) 0.67 
 
Right leg DVT 24  (22) 17 
 
(23) 7 
 
(18) 0.55 
 
Bilateral DVT 8  (7) 5 
 
(7) 3 
 
(8) 0.84 
  
   
       
Symptoms duration    
       
 
Acute (≤14 days) 97  (87) 68 
 
(93) 29 
 
(76) 
0.01 
 
Subacute (15 to 28 days) 14  (13) 5 
 
(7) 9 
 
(24) 
  
   
       
Thrombus, involved vein segments    
       
 
Inferior vena cava 22  (20) 16 
 
(22) 6 
 
(16) 0.44 
 
Common iliac vein 82  (74) 54 
 
(74) 28 
 
(74) 0.97 
 
External iliac vein 91  (82) 62 
 
(85) 29 
 
(76) 0.26 
 
Common femoral vein 79  (71) 54 
 
(74) 25 
 
(66) 0.37 
 
Femoral vein 51  (46) 37 
 
(51) 14 
 
(37) 0.17 
31  
1 
 
Popliteal vein 38  (34) 25 
 
(34) 13 
 
(34) 0.99 
 
Lower leg veins 12  (11) 8 
 
(11) 4 
 
(11) 0.94 
            
Note: data presented as mean ± SD or number (%). * defined as bed ridden for > 
72h, plaster cast, or long-distance travel of > 6h;  † oral contraceptive pill, hormone 
replacement therapy or Tamoxifen use; DVT, deep vein thrombosis;  VKA vitamin K-
antagonist; VTE, venous thromboembolism 
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Table 2. Procedural data and anticoagulation therapy  
 
  
Total                       
(n = 111) 
Rivaroxaban  
(n = 73) 
VKA  
(n = 38) 
P  
Value 
Type of catheter intervention 
         
0.20 
 
CDT* alone 54  (49) 40 
 
(55) 14 
 
(37) 
 
 
PMT alone 9  (8) 5 
 
(7) 4 
 
(11) 
 
 
Combination of CDT and PMT 48  (43) 28 
 
(38) 20 
 
(53) 
 
            
Catheter thrombolysis details 
          
 
Thrombolysis duration (h) 17.5 ± 6.9 17.9 ± 7.3 16.9 ± 6.0 0.49 
 
Thrombolysis dose (mg of r-tPA) 21.9 ± 7.6 22.7 ± 8.0 20.4 ± 6.9 0.17 
            
Thrombolysis success (% of thrombus load reduction) 
      
 
Complete (>90%) 45  (41) 30 
 
(41) 15 
 
(39) 0.97 
 
> 50% 40  (36) 27 
 
(37) 13 
 
(34) 
 
 
< 50% 15  (14) 10 
 
(14) 5 
 
(13) 
 
 
None 2  (2) 1 
 
(1) 1 
 
(3) 
 
            
Angioplasty and Venous stenting† 
          
 
- Mean number of stents 1.7 ± 1.1 1.6 ± 0.9 2.0 ± 1.4 0.09 
            
Anticoagulation, duration 
          
 
Limited duration 56  (50) 34 
 
(47) 22 
 
(58) 0.26 
 
- 3 months 22  (20) 17 
 
(23) 5 
 
(13) 
 
 
- 6 months 20  (18) 11 
 
(15) 9 
 
(24) 
 
 
- 12 months 14  (13) 6 
 
(8) 8 
 
(21) 
 
 - Mean duration of therapy (days) 219 ± 151 180 ± 98 284 ± 199 0.01 
 
Extended duration 44  (40) 33 
 
(45) 11 
 
(29) 0.10 
33  
 
 
 
 Duration not determined yet 11  (10) 6 
 
(8) 5 
 
(13) 0.41 
            
Note: data presented as mean ± SD or number (%). *including ultrasound-assisted 
CDT;  † Angioplasty without stenting was not performed. CDT, catheter-directed 
thrombolysis; LMWH, low-molecular-weight heparin; PMT, pharmacomechanical 
thrombectomy; r-tPA, recombinant tissue plasminogen activator; VKA, vitamin K-
antagonist 
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Table 3. Clinical outcomes at 6, 12, and 24 months follow-up  
  
Total                       
(n = 111) 
Rivaroxaban           
(n = 73) 
VKA             
(n = 38) 
P 
Value 
           
At 6 month follow-up n=86 
 
 n=60 
  
n=26 
  
 
 
Mean Villalta score 1.6 ± 2.0 1.8 ± 2.1 1.3 ± 1.7 0.27 
 
No PTS  78  (91) 53 
 
(88) 25 
 
(96) 0.50 
 
Mild PTS  7  (8) 6 
 
(10) 1 
 
(4)  
 
Moderate PTS  1  (1) 1 
 
(2) 0 
 
(0)  
 
Severe PTS 0 
 
(0) 0 
 
(0) 0 
 
(0)  
 
Mean rVCSS 2.5 ± 2.2 2.6 ± 2.3 2.2 ± 1.8 0.39 
           
 
At 12 month follow-up n=80 
  
n=49 
  
n=31 
  
 
 
Mean Villalta score 1.5 ± 1.7 1.5 ± 1.7 1.5 ± 1.6 0.84 
 
No PTS  75  (94) 46 
 
(94) 29 
 
(94) 0.95 
 
Mild PTS  5  (6) 3 
 
(6) 2 
 
(6)  
 
Moderate PTS  0 
 
(0) 0 
 
(0) 0 
 
(0)  
 
Severe PTS 0 
 
(0) 0 
 
(0) 0 
 
(0)  
 
Mean rVCSS 2.1 ± 2.1 2.2 ± 2.5 2.0 ± 1.6 0.73 
           
 
At 24 month follow-up n=56 
  
n=36 
  
n=20 
  
 
 
Mean Villalta score 1.6 ± 2.2 1.6 ± 2.5 1.8 ± 1.8 0.86 
 
No PTS  50  (89) 31 
 
(86) 19 
 
(95) 0.55 
 
Mild PTS  5  (9) 4 
 
(11) 1 
 
(5)  
 
Moderate PTS  1  (2) 1 
 
(3) 0 
 
(0)  
 
Severe PTS 0 
 
(0) 0 
 
(0) 0 
 
(0)  
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Mean rVCSS 2.2 ± 2.7 2.2 ± 3.0 2.5 ± 2.4 0.78 
           
 
Note: data presented as mean ± SD or number (%). PTS, post-thrombotic syndrome; 
rVCSS, revised venous clinical severity score; VKA, vitamin-K antagonist 
 
